Day

July 28, 2020
Exactis is pleased to be working with Dr. Jonathan Spicer on a phase I interventional pilot open-label trial, using rhDNase1 as a treatment for COVID-19 positive patients. The objectives are to assess the safety and feasibility of inhaled rhDNase1 in severely ill COVID-19 patients requiring admission, to evaluate the impact of rhDNase1 in limiting progression...
Read More
The Exactis-01 trial, a PMT sub-study “Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC within the Exactis Network” will be open at several PMT sites and Princess Margaret Hospital, the PI of the study is Dr. Jason Agulnik from...
Read More
The Exactis-03 trial “A  Phase I/II Basket Trial of the Combination of Veliparib and Navitoclax in  Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer” led by Dr. Helen MacKay from Sunnybrook Hospital, will be opened across PMT Network sites and Princess Margaret Hospital. Phase I will define the dose and schedule of navitoclax that can be combined safely with...
Read More
Sermonix Pharmaceuticals’ study “Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation.” The clinical trial is ongoing in the United States, and Exactis is currently performing a feasibility assessment across Canada to identify sites interested in participating in the study, if interested please contact dsalazar@exactis.ca.  https://clinicaltrials.gov/ct2/show/NCT03781063?term=sermonix&draw=2&rank=1
Read More
Exactis is pleased to be working with Dr. Sébastien Perreault from CHU Ste-Justine on the TRAM-01 study, “ Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway”. This study is led by Dr. Sébastien Perreault and the main objective is to determine...
Read More
Our new manuscript “Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition” is now available in Clinical Proteomics. Our research identified potential protein candidates for a blood-based prognostic signature of response to crizotinib in NSCLC patients harboring ALK fusion. https://doi.org/10.1186/s12014-020-9269-6 (Feb 2020) Publication: https://www.exactis.ca/2020/02/07/discovery-of-a-putative-blood-based-protein-signature-associated-with-response-to-alk-tyrosine-kinase-inhibition/
Read More